Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 73 results found. Search for [ bharat biotech covaxin phase 3 results ]

Results 20 to 40 of 73
BusinessToday.In
January 30, 2021
Serum Institute of India CEO Adar Poonawalla said the company's tie-up with American vaccine developer Novavax has published 'excellent efficacy results'


PTI
January 22, 2021
There were no serious side effects in the participants enrolled for the phase 1 trial of Covaxin, according to the results published in The Lancet


BusinessToday.In
January 5, 2021
Without naming Serum Institute CEO Adar Poonawalla, who had termed vaccines other than that of Pfizer, Moderna and Oxford-AstraZeneca as 'just like water', Krishna Ella said, 'We do 200 per cent honest clinical trials and yet we receive backlash'


BusinessToday.In
January 4, 2021
Bharat Biotech's Chairman and Managing Director Dr. Krishna Ella, in a press conference on Monday, January 5, clarified that its vaccine is safe and the company is conducting trials in over 12 countries besides India


BusinessToday.In
January 4, 2021
Cadila Healthcare share touched an intraday high of Rs 492.95, rising 3.02% against previous close of Rs 478.50 on BSE


BusinessToday.In
January 4, 2021
The phase-2 trials of Zydus Cadila's coronavirus vaccine had been conducted in around 1,000 healthy adults


BusinessToday.In
January 3, 2021
COVID-19 vaccines in India: Oxford-AstraZeneca's coronavirus vaccine Covishield and Bharat Biotech's COVID vaccine Covaxin will be India's first vaccines


BusinessToday.In
January 3, 2021
Coronavirus vaccine trials: Bharat Biotech said that it is steadily moving towards its goal of 26,000 volunteers. Phase 3 of human clinical trials for Covaxin began in mid-November


BusinessToday.In
January 2, 2021
The SEC has recommended Covaxin for emergency use authorisation; the recommendation, along with rollout modalities, will now be taken up by the DCGI for a final decision on the matter


BusinessToday.In
December 26, 2020
Pune-based SII is to submit an updated safety data of phase 2 and 3 clinical trials in India, immunogenicity data from the clinical trial in the UK and India, as well as the assessment results of the UK Medicines and Healthcare products Regulatory Agency


BusinessToday.In
December 25, 2020
COVAXIN also stated that promising results in the phase 1 and phase 2 trials of the Bharat Biotech COVID-19 vaccine have led to the phase 3 trials


Reuters
December 24, 2020
Brazil is the first country to complete a late-stage trial of the vaccine, called CoronaVac, but a release of the results, first set for early December, has now been delayed three times


PTI
December 24, 2020
Covaxin, being developed in collaboration with the Indian Council of Medical Research and the National Institute of Virology, is now undergoing phase-3 trials


BusinessToday.In
December 22, 2020
The Phase 3 clinical trials of Covaxin began in mid-November with a target of 26,000 volunteers. Bharat Biotech's is the first and only Phase 3 efficacy study for a vaccine developed in the country


BusinessToday.In
December 9, 2020
Several experts have raised questions about Bharat Biotech applying for emergency usage as Covaxin is still going through an efficacy trial. However, the ICMR has backed Bharat Biotech's move


BusinessToday.In
December 4, 2020
COVID-19 vaccine trial updates: AIIMS director Dr Randeep Guleria has pinned his hopes on the five coronavirus vaccine candidates which are in varying stages of trials across India


BusinessToday.In
November 30, 2020
There are only five companies that have given preliminary data about how effective their vaccines could be to fight against coronavirus. These five companies include Pfizer-BioTech, Moderna Inc, Oxford University-AstraZeneca Plc, and Gamaleya Institute


PB Jayakumar
November 28, 2020
Prime Minister Narendra Modi's visit to these facilities and discussions with the scientists are to help him get a first-hand perspective of the preparations, challenges and roadmap in India's vaccination plans


BusinessToday.In
November 27, 2020
After the publication of early data from phase-3 clinical trials, drugmakers Pfizer and BioNTech have sought regulatory approval to deploy their inoculation under emergency-use rules. American biotech company Moderna is also likely to do the same soon


BusinessToday.In
November 24, 2020
Vardhan says it makes no sense to consider Pfizer as pharma major is yet to get approval in the US. After requisite approvals, US pharma major will have to cater to needs of its own country's population first


PAGES 2 OF 4  1234